Considering pathways associated to anti-cancer agent resistance treatments, some target genes were enrichment in antifolate resistance (8 target genes), platinum drug resistance (18 target genes), PD-L1 expression and PD-1 checkpoint (26 target genes), and EGFR tyrosine kinase inhibitor resistance (34 target genes) pathways (Supplementary Table S4). The gene discussed is EGFR; the disease is cancer.